Biogen executives stated at a Wells Fargo conference that the company is focused on moving beyond its traditional emphasis on neurology, advancing a broader late-stage pipeline, and managing expenses to seek a return to growth. The company currently has 10 Phase III programs, with results expected to begin being announced in the fourth quarter. Biogen anticipates approximately $250 million in annual cost savings next year and plans to expand its business into immunology and nephrology through acquisitions such as HI-Bio and Apellis.